Stoke Therapeutics details 2024 clinical milestones; STK-001 data in Q1, STK-002 trial in UK

Stoke Therapeutics, Inc.

In Q1 2024, plans to report safety, PK, and CSF results from 81 patients in STK-001 Phase 1/2a and OLE studies.
Seizure frequency data from ~20 patients who received 1-3 doses of 70mg STK-001, followed for six months, will be released in Q1.
Repeat dose effects (30mg, 45mg) on seizure frequency and cognition/behavior from OLE studies also expected in Q1.
Depending on Q1 results, plans to start Phase 3 preparation including regulatory discussions and toxicology data.
Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy expected to begin in UK in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.